Validation of VitBOD, a simple burden of disease instrument for vitiligo
Main Article Content
Background: Vitiligo is a chronic, progressive condition of skin depigmentation that has a negative impact on quality of life.
Aim of the study: To validate a novel, low-burden tool to more accurately assess the burden of disease on those affected.
Methods: The VitBOD was designed as a ten question tool using visual analog scales to assess various physical, mental and emotional domains of health specific to vitiligo. 90 subjects with dermatologist-confirmed vitiligo agreed to complete the self-administered VitBOD questionnaire along with the previously validated Short Form-36 (SF-36).
Results: 67 fully completed questionnaires were returned. VitBOD scores were transformed to fit the direction of the SF-36 for statistical analysis. Median overall scores were significantly lower for VitBOD as shown by the paired t-test (75.3 vs 85, p=0.015). VitBOD showed high internal consistency (Cronbach’s alpha = 0.9). Vitality, social, and mental health domains correlated positively with SF-36.
Conclusion: VitBOD can reliably measure burden of disease in vitiligo as well as the SF-36 with distinct advantages being ease and speed of use along with disease-specificity. Testing in broader patient populations would be useful for further validation.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
1. Bhandarkar, SS, Kundu, RV. Quality-of-life issues in vitiligo. Dermatol Clin, 2012; 2: 255-68.
2. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015; Jan 14.
3. Shankar, DS, Shashikala, K, Madala, R. Clinical patterns of vitiligo and its associated co morbidities: A prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012; 3(2): 114-8.
4. Wang, KY, Wang, KH, Zhang, ZP. Health- related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol 2011; 25(4): 429-35.
5. Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gend Med 2006; 3(2): 124-30.
6. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5(2):105-10.
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 3:210-6.
8. Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol 1997; 37(1):41-50.
9. Lilly, E, Lu, PD, Borovicka, JH, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 2013; 69(1):e11-8.
10. Krishna GS, Ramam M, Mehta M, et al. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo. Indian J Dermatol Venereol Leprol 2013; 79(2):205-10.
11. Gupta V, Sreenivas V, Mehta M, et al. Measurement properties of the Vitiligo Impact Scale-22 (VIS-22), a vitiligo-specific quality-of-life instrument. Br J Dermatol 2014; 171(5):1084-90.
12. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305(6846):160-4.
13. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41(3):151-8.
14. Tabolli S1, Mozzetta A, Antinone V, et al. The health impact of pemphigus vulgaris and pemphigus foliaceus assessed using the Medical Outcomes Study 36-item short form health survey questionnaire. Br J Dermatol 2008; 158(5):1029-34.
15. Ahmed A, Leon A, Butler DC, Reichenberg J. Quality of side effects of common dermatological diseases. Semin Cutan Med Surg. 2013; 32(2):101-9.